Two people can take the same medicine and have different experiences. One may notice a large weight change, while the other sees a smaller change or has more side effects. Could a DNA test tell them which person they’ll be?
Genes may contribute to those differences, and researchers have found associations worth studying. A genetic association is not a personal forecast, though. The evidence from a study does not automatically validate every commercial test or tell one individual exactly how much weight they will lose.
What are researchers looking for?
Genes contain instructions involved in many processes throughout the body. Researchers can look for variations that occur more often in people who report one treatment response than another.
Some work focuses on genes connected to the pathways targeted by GLP-1-related medicines. That makes biological sense as a research question, but a person’s experience can also reflect their health history, the specific treatment, time taking it, side effects, access and many other factors.
An association across a group doesn’t mean a gene acts alone. It also doesn’t tell you whether a prediction is accurate enough to guide a treatment decision.
What did a larger study find?
One genome-wide study examined self-reported weight changes and side effects from 27,885 people who had used GLP-1-related medicines. Researchers identified associations involving genetic variation in drug-target pathways, including a variant linked with a difference in average weight response.
That is a substantial research population, but the outcomes were self-reported. People may remember or report their experiences differently, and a group average can overlap considerably with the experiences of people in another group.
The researchers also explored a model to group people by response and side-effect likelihood. More work is needed to determine how well any particular approach works in different populations and whether using it improves actual care decisions.
A smaller study adds another piece
Another study genotyped 112 adults with severe obesity who had been treated with semaglutide. Researchers reported differences in average weight-loss patterns associated with one receptor-gene variant and sex.
The groups were small, and this was not a randomized test of whether choosing treatment based on the gene improves outcomes. A study can reveal a signal worth following without supplying a reliable prediction for every person.
Before paying for a test
Ask what the test claims to predict and which published studies support that exact claim. Was it evaluated in people like you? Does it address the specific medicine you’re considering? Has anyone shown that using the result leads to better decisions or outcomes?
Also ask what information the company collects, how it stores genetic data and what the test costs. A polished report and a precise-looking percentage are not proof that the prediction will be accurate for you.
Your clinician can help interpret a result in the context of your medical history. It may be more useful to review the medicine you’re taking, your experience of side effects, practical access and follow-up than to assume a single marker explains everything.
What if your response is different from someone else’s?
That difference isn’t a verdict on your effort. Our guide to why GLP-1 weight-loss results differ between people covers factors you can discuss with your care team.
Keep a record of the things that matter to you, such as appetite, comfort, daily function and any weight trend you’ve agreed to track. Bring questions to follow-up rather than changing a dose based on a genetic report.
Genetic research is moving quickly. For now, the most useful distinction is between a finding that helps scientists understand a group and a tool that has been shown to improve decisions for an individual.